AGOURA HILLS, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB: MATN) today announced financial results for the third quarter ended September 30, 2020 (“Q3 2020”), as well as an update on its therapeutic development initiatives, including those related to COVID-19.
Recent Operational Highlights
| ● | ArtiShield™ (outside of India)/ARTIVeda™ (India) | ||
| o | Signed an agreement with Windlas Biotech Pvt. Ltd. of India to commercialize ArtiShield™ /ARTIVeda™, the Company’s lead ethnobiology dru,g designed to be a readily available and cost-effective agent to combat COVID-19; | ||
| o | ArtiShield™ /ARTIVeda™ approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy), license number UK.AY-401/2018, for the treatment of various symptoms like fever and inflammation frequently seen in… | ||
